Observational Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Nov 27, 2024; 16(11): 1282-1289
Published online Nov 27, 2024. doi: 10.4254/wjh.v16.i11.1282
Overexpression of proteasome 26S subunit non-ATPase 6 protein and its clinicopathological significance in intrahepatic cholangiocarcinoma
Zhong-Qing Tang, Yu-Lu Tang, Kai Qin, Qi Li, Gang Chen, Yu-Bin Huang, Jian-Jun Li
Zhong-Qing Tang, Department of Pathology, Wuzhou Gongren Hospital/The Seventh Affiliated Hospital of Guangxi Medical University, Wuzhou 543000, Guangxi Zhuang Autonomous Region, China
Yu-Lu Tang, Kai Qin, Qi Li, Gang Chen, Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Yu-Bin Huang, Jian-Jun Li, Department of General Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530007, Guangxi Zhuang Autonomous Region, China
Co-first authors: Zhong-Qing Tang and Yu-Lu Tang.
Author contributions: Tang ZQ, Tang YL, and Li JJ conceived and designed the study; Qin K analyzed the data and prepared all the graphs; Li Q, Chen G, and Huang YB provided technical support and experimental materials; Tang ZQ and Tang YL drafted the manuscript; Li JJ revised the manuscript. The decision for co-first authorship is based on the substantial and equal contributions of Tang ZQ and Tang YL to the conception, design, execution, and interpretation of the research presented in this manuscript. Both authors have played a crucial role in drafting and revising the manuscript and have approved the final version. Both authors actively participated in the preparation of the manuscript and are equally accountable for its content.
Institutional review board statement: The protocol for this research project has been approved by a suitably constituted Ethics Committee of the institution Committee of Pantomics, Inc. [Approval No. Fanpu(2018)23].
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that there are no financial conflicts of interest to disclose.
Data sharing statement: The data that support the findings of this study are available from the corresponding author at lijianjunmail@163.com upon reasonable request.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian-Jun Li, PhD, Surgeon, Department of General Surgery, The Second Affiliated Hospital of Guangxi Medical University, No. 166 East University Road, Xixiangtang District, Nanning 530007, Guangxi Zhuang Autonomous Region, China. lijianjunmail@163.com
Received: May 25, 2024
Revised: June 23, 2024
Accepted: July 23, 2024
Published online: November 27, 2024
Processing time: 164 Days and 19.8 Hours
Abstract
BACKGROUND

Currently, intrahepatic cholangiocarcinoma (ICC) poses a continuing, significant health challenge, but the relationship has yet to be established between ICC and the proteasome 26S subunit non-ATPase 6 (PSMD6).

AIM

To investigate the protein expression and clinicopathological significance of PSMD6 in ICC.

METHODS

The potential impact of the PSMD6 gene on the growth of ICC cell lines was analyzed using clustered regularly interspaced short palindromic repeat knockout screening technology. Forty-two paired specimens of ICC and adjacent non-cancerous tissues were collected. PSMD6 protein expression was determined by immunohistochemistry. Receiver operating characteristic curve analysis was performed to validate PSMD6 expression level, and its association with ICC patients’ various clinicopathological characteristics was investigated.

RESULTS

The PSMD6 gene was found to be essential for the growth of ICC cell lines. PSMD6 protein was significantly overexpressed in ICC tissues (P < 0.001), but showed no significant association with patient age, gender, pathological grade, or tumor-node-metastasis stage (P > 0.05).

CONCLUSION

PSMD6 can promote the growth of ICC cells, thus playing a pro-oncogenic role.

Keywords: Intrahepatic cholangiocarcinoma; Proteasome 26S subunit non-ATPase 6; Immunohistochemistry; Clustered regularly interspaced short palindromic repeat knockout screening; Clinicopathological characteristics

Core Tip: This study examined the expression and clinicopathological significance of proteasome 26S subunit non-ATPase 6 (PSMD6) in intrahepatic cholangiocarcinoma (ICC). It was discovered that the PSMD6 gene was essential for the proliferation of ICC cell lines. Furthermore, PSMD6 protein expression was significantly elevated in ICC specimens (P < 0.001), although it was not significantly correlated with patient age, gender, pathological grade, or tumor-node-metastasis stage (P > 0.05). These results indicate that PSMD6 may enhance the proliferation of ICC cells, thereby contributing to its oncogenic potential.